Cardiovascular effects of paroxetine, a newly developed antidepressant, in anesthetized dogs in comparison with those of imipramine, amitriptyline and clomipramine
- PMID: 2963926
- DOI: 10.1254/jjp.45.335
Cardiovascular effects of paroxetine, a newly developed antidepressant, in anesthetized dogs in comparison with those of imipramine, amitriptyline and clomipramine
Abstract
The cardiovascular effects of various antidepressant drugs including paroxetine, imipramine, amitriptyline and clomipramine, administered intravenously, have been assessed. Paroxetine, imipramine, amitriptyline or clomipramine potentiated the response to norepinephrine (0.1 microgram/kg, i.v.) on systemic blood pressure, while paroxetine, imipramine and amitriptyline weakened the response to tyramine (30 micrograms/kg, i.v.). A marked decrease in systemic blood pressure was observed after large doses of each drug (3 and 10 mg/kg of paroxetine; 1-10 mg/kg of imipramine, amitriptyline or clomipramine); and half of the animals died following administration of 10 mg/kg of imipramine, amitriptyline or clomipramine. Paroxetine did not show a marked effect on heart rate at a dose of up to 3 mg/kg, although 0.1-3 mg/kg of imipramine, amitriptyline or clomipramine dose-dependently caused tachycardia. ECG disturbances were observed in animals administered 10 mg/kg of imipramine, amitriptyline or clomipramine; but in contrast, 10 mg/kg of paroxetine caused only slight changes in the ECG. Prolongation of atrio-ventricular conduction time was observed with all the drugs. It was concluded that the effects of paroxetine on the canine heart are more mild in comparison with other tricyclic antidepressants used, although its pharmacological features are essentially similar to those of other drugs.
Similar articles
-
Comparison of the cardiovascular effects of amineptine with those of amitriptyline and imipramine in anaesthetized rats.Arch Int Pharmacodyn Ther. 1991 Jan-Feb;309:64-74. Arch Int Pharmacodyn Ther. 1991. PMID: 1888231
-
Cardiovascular and anticholinergic effects of zimelidine.Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(4-6):403-6. doi: 10.1016/s0278-5846(82)80116-4. Prog Neuropsychopharmacol Biol Psychiatry. 1982. PMID: 6219432
-
Comparison of some effects of paroxetine with amitriptyline on the cardiovascular system in animals.Arzneimittelforschung. 1986 Mar;36(3):460-3. Arzneimittelforschung. 1986. PMID: 2939838
-
Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.Drugs. 1991 Feb;41(2):225-53. doi: 10.2165/00003495-199141020-00007. Drugs. 1991. PMID: 1709852 Review.
-
An overview of the animal pharmacology of paroxetine.Acta Psychiatr Scand Suppl. 1989;350:14-20. doi: 10.1111/j.1600-0447.1989.tb07161.x. Acta Psychiatr Scand Suppl. 1989. PMID: 2530769 Review.
Cited by
-
A case report on the safety and efficacy of aripiprazole for depression in Brugada syndrome.Ment Health Clin. 2025 Apr 4;15(2):62-68. doi: 10.9740/mhc.2025.04.062. eCollection 2025 Apr 1. Ment Health Clin. 2025. PMID: 40224518 Free PMC article.
-
Paradigms for pharmacologic use as a treatment component in feline behavioral medicine.J Feline Med Surg. 2004 Feb;6(1):29-42. doi: 10.1016/j.jfms.2003.09.009. J Feline Med Surg. 2004. PMID: 15123164 Free PMC article. Review.
-
Cardiovascular effects of paroxetine.Psychopharmacology (Berl). 1990;102(3):379-82. doi: 10.1007/BF02244107. Psychopharmacology (Berl). 1990. PMID: 2147517 Clinical Trial.
-
The Antidepressant Paroxetine Reduces the Cardiac Sodium Current.Int J Mol Sci. 2023 Jan 18;24(3):1904. doi: 10.3390/ijms24031904. Int J Mol Sci. 2023. PMID: 36768229 Free PMC article.
-
Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy.Drugs Aging. 1993 May-Jun;3(3):278-99. doi: 10.2165/00002512-199303030-00008. Drugs Aging. 1993. PMID: 8324301 Review.